2021 | International evidence base | Systematic review and meta-analysis
Wang L et al. BMJ. 2021;374:n1034.
Methods: Researchers synthesized 32 randomized trials involving 5,174 adults with chronic pain. Products were non-inhaled, mostly oral, and follow-up ranged from one to 5.5 months. The review assessed pain, functioning, sleep, and adverse effects.
Findings: Average pain improvement over placebo was about half a point on a 0 to 10 scale. Improvements in physical function and sleep were generally small. Dizziness, drowsiness, nausea, and other adverse effects were more frequent with cannabinoids.
Limitations: The trials were relatively short and used different products and patient populations. These estimates cannot establish the effects of smoked cannabis or long-term treatment.
